Bucillamine

Research use only, not for human use.

Bucillamine protects against Ischemia/reperfusion injury in high-risk organ transplants and inhibits the production of VEGF.

Bucillamine protects against Ischemia/reperfusion injury in high-risk organ transplants and inhibits the production of VEGF. Bucillamine is an orally active sulfhydryl donor and antioxidant with antirheumatic and antiangiogenic properties. Bucillamine can be used for studies about choroidal neovascularization and rheumatoid arthritis.(In Vivo):In rats subjected to liver transplants, Bucillamine significantly enhances survival and protected against hepatic injury. Subconjunctival injection of Bucillamine significantly reduces the leakage and size of experimental CNV in rats.

——

Bucillamine significantly enhances survival and protected against hepatic injury in rats subjected to liver transplants.Bucillamine (Subconjunctival injection) significantly reduces the leakage and size of experimental CNV in rats.

DE-019 | DE 019 | DE019 | SA96 | Thiobutarit | Tiobutarit |

Angiogenesis

VEGFR

Endogenous Metabolite

——

——

65002-17-7

223.31

C7H13NO3S2

>98% (HPLC)

In Vitro:?H2O : 5 mg/mL (22.39 mM)

CC(C)(S)C(=O)NC(CS)C(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years